Hansa Medical AB has appointed Søren Tulstrup as its new chief executive, effective 20 March, following the unexpected death of the CEO Göran Arvidson in 2017. Mr Tulstrup will oversee the late-stage development and registration of the company’s product to enable high-risk kidney transplants. Most recently, he was CEO of Vifor Pharma AG of Switzerland which has a marketed product for chronic kidney disease.
Copyright 2018 Evernow Publishing Ltd